Differential expression of Gs in a murine model of homocysteinemic heart failure

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 79-84

  Vacek, Thomas P ^a   Sen, Utpal ^a   Tyagi, Neetu ^a   Vacek, Jonathan C ^a   Kumar, Munish ^a   Hughes, William M ^a   Passmore, John C ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

G proteins; GPCR; Heart failure; HL 1; Homocysteine

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; G PROTEIN COUPLED RECEPTOR; HOMOCYSTEINE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; HEART FAILURE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; CALCIUM SIGNALING; CELL LINE; DISEASE MODEL; GENETICS; HEART MUSCLE; HYPERHOMOCYSTEINEMIA; MALE; METABOLISM; MOUSE MUTANT;

ANIMALS; CALCIUM SIGNALING; CELL LINE, TRANSFORMED; CYSTATHIONINE BETA-SYNTHASE; DISEASE MODELS, ANIMAL; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HEART FAILURE; HYPERHOMOCYSTEINEMIA; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM;

EID: 67449094498     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Refsum, H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.
2. Seshadri S. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Eng J Med. 2002;346:476-83.
3. Ovechkin AV, Tyagi N, Sen U, Lominadze D. 3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Physiol. 2006;291:L905-11.
4. Herrmann M, Taban-Shomal O, Hübner U, Böhm M, Herrmann W. A review of homocysteine and heart failure. Eur J Heart Fail. 2006;8:571-6.
5. Ni M, Zhang XH, Jiang SL, Zhang Y. Homocystinemia as an independent risk factor in the Chinese population at a high risk of coronary artery disease. Am J Cardiology. 2007;100:455-8.
6. Gibelin P, Serre S, Candito M, et al. Prognostic value of homocysteinemia in patients with congestive heart failure. Clin Chem Lab Med. 2006;44:813-16.
7. Rasouli ML, Nasir K, Blumenthal RS, Park R, Aziz DC, Budoff MJ. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis. 2005;181:159-65.
8. Joseph J, Joseph L, Shekhawat NS, et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Phsyiol Heart Circ Physiol. 2003;285:H679-86.
9. Herrmann M, Kindermann I, Müller S, et al. Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem. 2005;51:1512-15.
10. Moshal KS, Sen U, Tyagi N, et al. Regulation of homocysteine-induced MMP-9 by ERK 1/2 pathway. Am J Physiol Cell Physiol. 2006;290: C883-91.
11. Gough N. STKE focus issue on GPCRs: The evolution of G proteincoupled receptor signaling. Sci STKE. 2001;104:1-2.
12. Post S, Hammond K, Insel P. adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol. 1999;39:343-60.
13. Lohse M, Engelhardt S, Eschenhagen T. What is the role of B-adrenergic signaling in heart failure? Circ Res. 2003;93:896-906.
14. Lader AS, Xiao YF, Ishikawa Y, et al. Cardiac Gsalpha overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway. Proc Natl Acad Sci U S A. 1998;95:9669-74.
15. Hardt S, Geng Y-J, Montagne O, et al. Accelerated cardiomyopathy in mice with overexpression of cardiac Gsalpha and a missense mutation in the alpha-myosin heavy chain. Circulation. 2002;105:614-20.
16. Ovechkin AV, Tyagi N, Sen U, Lominadze D, Steed MM, Moshal KS. 3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Phsyiol. 2006;291:L905-11.
17. Filizola M, Weinstein H. The structure and dynamics of GPCR oligomers: a new focus in models of cell-signaling mechanisms and drug design. Curr Opin Drug Discov Devel. 2005;8:577-84.
18. Luttrell LM. Transmembrane signaling by G protein-coupled receptors. Methods Mol Biol. 2006;332:3-49.
19. Natarajan K, Berk BC. Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol. 2006;332:51-77.
20. Barros Rde A, Okoshi MP, Cicogna AC. Beta-adrenergic pathway in healthy and hypertrophied hearts. Arq Bras Cardiol. 1999;72:649-56.
21. He J-G, Balijepalli R, Haworth R, et al. Crosstalk of B-adrenergic receptor subtypes through Gi blunts B-adrenergic stimulation of L-type Ca2+ channels in canine heart failure. Circ Res. 2005;97:566-73.
22. Finney PA, Belvisi MG, Donnelly LE, et al. Albuterol-induced down-regulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo. J Clin Invest. 2000;106:125-35.
23. Finney P, Donnelly L, Belvisi M, et al. Chronic systemic administration of salmeterol to rats promotes pulmonary B2-adrenoceptor desensitization and down-regulation of Gsalpha. Br J Pharmacol. 2001;132:1261-70.
24. Allen JA, Yu JZ, Donati RJ, Rasenick MM. Beta-adrenergic receptor stimulation promotes G alpha s internalization through lipid rafts: a study in living cells: a study in living cells. Mol Pharmacol. 2005;67:1493-504.
25. Hammond HK. Mechanisms for myocardial B-adrenergic receptor desensitization in heart failure. Circulation. 1993;87:652-4.
26. Foerster K, Groner F, Matthes J, Koch WJ, Birnbaumer L, Herzig S. Cardioprotection specific for the G protein Gi2 in chronic adrenergic singaling through B2-adrenoceptors. Proc Natl Acad Sci U S A. 2003;100:14475-80.
27. Asai K, Yang G-P, Geng Y-J, et al. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gs mouse. J Clin Invest. 1999;104:551-8.
28. Di Fusco F, Hashim S, Anand-Srivastava M. Volume overload cardiac hypertrophy exhibits decreased expression of Gsalpha and not of Gialpha in heart. Am J Physiol Cell Physiol. 2000;279:C990-8.
29. Joseph J, Joseph L, Shekhawat NS. et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol. 2003;285:H679-86.
30. Kassab S, Garadah T, Abu-Hijleh M, et al. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats. J Renin Angiotensin Aldosterone Syst. 2006;7:206-11.
31. Poyrazoǧlu HM, Düşünsel R, Narin F, et al. Homocysteine and left ventricular hypertrophy in children with chronic renal failure. Pediatr Nephrol. 2004;19:193-8.
32. Ruan H, Mitchell S, Vainoriene M, et al. Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. Circulation. 2007;116:596-605.
33. Blumenstein Y, Ivanina T, Shistik E, et al. Regulation of cardiac L-type Ca2+ channel by coexpression of Galphas in xenopus oocytes. FEBS Lett. 1999;444:78-84.